Hematology TimesPotential therapeutic strategy for BL, DLBCLMarch 2, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesDrug granted orphan status for follicular lymphomaFebruary 24, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesFactors linked to B-NHL in Palestinians, IsraelisFebruary 23, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesEuropean Commission approves rituximab biosimilarFebruary 23, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesDrug produces high response rates in AITLFebruary 16, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesObinutuzumab approved to treat FL in CanadaFebruary 8, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsCirculating DNA catches lymphoma relapse earlyJanuary 29, 2017Aggressive LymphomasLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesStudy provides new insight into B-cell metabolismJanuary 29, 2017Lymphoma & Plasma Cell DisordersAggressive LymphomasFollicular Lymphoma
Hematology TimesCombined checkpoint blockade promising in HLDecember 22, 2016Lymphoma & Plasma Cell DisordersHodgkin LymphomaFollicular Lymphoma
Hematology TimesJCAR017 gets PRIME access, breakthrough designationDecember 21, 2016Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesCAR met primary endpoint at interim analysis in DLBCLDecember 16, 2016Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesCharacterizing FL transformation, progressionDecember 15, 2016Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology NewsVIDEO: Obinutuzumab bests rituximab for PFS in follicular lymphomaDecember 6, 2016Indolent LymphomaLymphoma & Plasma Cell DisordersMantle Cell LymphomaFollicular Lymphoma
Hematology NewsAntibody face-off in follicular lymphoma gives PFS, but not OS, edge to obinutuzumabDecember 5, 2016Indolent LymphomaLymphoma & Plasma Cell DisordersMantle Cell LymphomaFollicular Lymphoma
Hematology TimesTazemetostat receives fast track designation for DLBCLNovember 29, 2016Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaFollicular Lymphoma
